Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

Distribution of access to obesity pharmacotherapy — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-035/5
Series
Evidence synthesis
Version
1.3
Published
05 Nov 2024
Last reviewed
05 Mar 2025
Next review
05 Sep 2026
Identifier
10.71829/cei.syn.35
Certainty
Low
Cycle
2024 Q4
Review type
Methodological review
Search executed
11 Sep 2024

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
16 Aug 20240.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
23 Feb 20251.1Comment-period disposition appliedAmendments arising from the disposition of a public comment period were applied. Each amendment is traceable to a numbered submission.
04 Sep 20251.2Correction issuedA numerical error in one summary-of-findings row was corrected. The direction of the conclusion was unaffected and the correction is recorded in full in the corrections log.
23 Feb 20261.3Study reclassifiedA study previously included was reclassified as ineligible following retrieval of the full report. The quantitative synthesis was re-run without it.
Current version 1.3, ratified in the 2024 Q4 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
ATTAIN-123 Jun 2024Refused
ATTAIN-207 Aug 2024Refused
ECNO-PH3-CN-OBESITY06 Aug 2024Supplied on request
GLORY-110 Aug 2024Refused
REDEFINE-108 Aug 2024Refused
REDEFINE-210 Aug 2024Refused
SURMOUNT-525 Jul 2024Supplied on request
SURMOUNT-KOA06 Aug 2024No response

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.